Please login to the form below
tocilizumab
This page shows the latest tocilizumab news and features for those working in and with pharma, biotech and healthcare.
NICE publishes final draft guidance recommending three COVID-19 treatments
The agency’s latest guidance recommends the use of Pfizer’s Paxlovid (tirmatrelvir plus ritonavir), GSK’s Xevudy (sotrovimab) and Roche’s RoActemra (tocilizumab).
Latest news
-
Roche’s COVID-19 antibody receives FDA approval for hospitalised adults
Roche’s Actemra (tocilizumab) has been approved by the US Food and Drug Administration (FDA) for the treatment of COVID-19 in hospitalised adults, the company announced.
-
NICE publishes draft guidance recommending three COVID-19 treatments
The treatments recommended by NICE are Roche’s RoActemra (tocilizumab) and Eli Lilly’s Olumiant (baricitinib), both indicated for use in a hospitalised setting in patients requiring supplemental oxygen, as well
-
Sobi’s Kineret granted FDA Emergency Use Authorisation for COVID-19 related pneumonia
This includes Roche’s Actemra (tocilizumab), which was granted EUA by the FDA in June 2021 to be used alongside corticosteroids for hospitalised patients requiring oxygen support.
-
Results from trial show Eli Lilly’s COVID-19 drug improves survival rates
The benefit of baricitinib proved to be consistent regardless of which other COVID-19 treatments the patients were also receiving, including tocilizumab, corticosteroids or remdesivir. ... other treatments that dampen down the overactive immune response,
-
WHO issues prequalification for Roche’s Actemra/RoActemra for severe or critical COVID-19
The World Health Organization (WHO) has issued a prequalification for Roche’s Actemra/RoActemra (tocilizumab).
More from news
Approximately 8 fully matching, plus 71 partially matching documents found.
Latest Intelligence
-
As COVID-19 takes over the world, biopharma fights back
In early March, China approved the use of Roche’s Actemra (tocilizumab) for the treatment of COVID-19 patients who develop serious lung damage, and also have elevated IL-6 levels
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
Latest from PMHub
-
Brand leaders in RA will lose market share, predict rheumatologists
leaders Enbrel (etanercept) and Humira (adalimumab) will continue to lose market share to newer biologics such as RoActemra (tocilizumab), Orencia (abatacept) and Simponi (golimumab) and may experience strong competition from biosimilar
More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.
Subscribe to our email news alerts
- Home Based Account Manager, Medical Communications, UK, Pharma/M...
- Highly competitive salary
- Account Manager, Healthcare Marketing Creative Agency, Fixed ter...
- Highly competitive salary
- Account Manager, 6 month contract, Healthcare Brand communicatio...
- Highly competitive salary
- Market Access Director, six figure base salary and £5K joining b...
- Highly competitive salary
- Senior Medical Copywriter - Highly Awarded Advertising Agency
- £50,000 - £60,000 yearly
- Account Director, Healthcare Marketing Creative Agency, Fixed te...
- Highly competitive salary
- Novartis receives EC approval for Cosentyx in hidradenitis suppurativa
- BMS and Janssen’s antithrombotic granted FDA fast track designation
- Sanofi's frexalimab shows promise in relapsing forms of MS
- Amgen reports positive results for Otezla in psoriatic arthritis
- EMA recommends revoking marketing authorisation for Novartis’ sickle cell disease drug
- How an AI algorithm might save your life
- Whitepaper: Closing the gap with compelling healthcare communications
- Pfizer’s antibiotic combination shows promise in treating multi-drug resistant infections
- Supporting the most vulnerable: why pharma should get behind the NHS’ healthcare equity campaign
- Healing the Healers
- The (inevitable) digital transformation of Medical Affairs
- Novartis receives EC approval for Cosentyx in hidradenitis suppurativa
No results were found
PMHub
Genesis Research
Genesis Research is an international HEOR and RWE research organization. A leader in evidence strategy, generation and communication, the company...
Latest intelligence
- Whitepaper: Closing the gap with compelling healthcare communications
- Want to learn how to close the distance between a person’s current health and their healthiest possible self?...
- Healing the Healers
- Because if we do not heal the healers, who is going to heal us?...
- The (inevitable) digital transformation of Medical Affairs
- It’s not a question of ‘if,’ it’s a question of ‘when.’...
